Cipla

1st August 2016

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sirs,

Please find enclosed press release dated 1st August 2016.

Thank you,

Yours faithfully,
For Cipla Limited

M. A. Sanghvi

Mital Sanghvi
Company Secretary

Press Release

Cipla appoints Kedar Upadhye as Global Chief Financial Officer

India, Mumbai, August 1, 2016: Today, Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, is delighted to announce the appointment of Kedar Upadhye as the Global Chief Financial Officer of the Company effective August 1, 2016.

Kedar is a qualified Cost Accountant with a follow-on MBA from IIM Bangalore. He brings with him deep experience of the global generics business. Until recently, Kedar was Vice President, Global Generics Finance and Head of Investor Relations in Dr Reddy's. Prior to Dr Reddy's, he has worked with Pepsi India and Thermax Group.

Commenting on his appointment, Subhanu Saxena, MD and Global CEO, Cipla Ltd said, "We are pleased to welcome Kedar Upadhye to Cipla's leadership team. With his strong financial expertise and deep insights about the global generics industry, he shall be a strong addition to our Management Council to help us move forward towards our aspirations."

With Kedar joining Cipla and assuming the responsibility of Global CFO, Umang Vohra will cease to be the Global CFO of the Company. Umang will continue to be the Global Chief Operating Officer.

About Cipla Ltd.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems.

Media Contacts:
Corporate Communications
Pallavi Golar
Mobile: +91 9833641788
E Mail: pallavi.golar@cipla.com